Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124
Status:
Recruiting
Trial end date:
2023-11-22
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multicenter, open-label extension (OLE) study to evaluate the long-term
safety, tolerability, and effectiveness of CIN-107 for up to 52 weeks in patients with HTN
who have completed Part 1 or Part 2 of Study CIN-107-124. The study will be conducted at
clinical sites that have participated in the double-blind, Phase 2 Study CIN-107-124.